Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010

Queenan, Anne Marie; Pillar, Chris M.; Deane, Jennifer; Sahm, Daniel F.; Lynch, A. Simon; Flamm, Robert K.; Peterson, Janet; Davies, Todd A.

doi:10.1016/j.diagmicrobio.2012.04.002

Cited by 69 publications

(63 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colistin (polymyxin E), to which A. baumannii sensitivity was found to be 90% in our study, is becoming an alternative for β-lactam antibiotics. This data coincides with the results of the American CAPITAL study of 2010, where sensitivity to colistin was found to be 95% (16).…”

Section: Discussionsupporting

confidence: 80%

“…In the years 1998-2001, the percentage of carbapenem-sensitive isolates in the USA was 90% (1, 14). Studies from recent years concerning A. baumannii infections at hospitals in the USA and South Korea confirm a decline in the susceptibility of A. baumannii strains to 50% (3,15,16). The MYSTIC program con-In an ex vivo study conducted in 2008 in Argentina, the therapeutically effective bactericidal concentration of ampicilin combined with sulbactam was achieved for 0.5g and 1g doses of sulbactam administered every 4 hours.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Acinetobacter Baumannii Nosocomial Infections

Sieniawski¹,

Kaczka²,

Rucińska³

et al. 2013

Polish Journal of Surgery

View full text Add to dashboard Cite

Nosocomial infections caused by strains Acinetobacter baumannii strands are a growing clinical problem.The occurrence of multidrug-resistant strands is observed and that limits the ways of therapy considerably. the aim of the study was to determine the rate of infection and susceptibility spectrum of the species Acinetobacter baumannii isolated from patients treated at Maria Skłodowska-Curie Memorial Hospital in Zgierz with particular emphasis on surgical wards. Materials and methods. The material consisted of Acinetobacter baumannii isolates were obtained from samples of materials from patients treated at Maria Skłodowska-Curie Memorial Hospital in Zgierz from January to December 2011. Isolated bacterial strains were cultured at microbiological substrates. Isolates were identified to species using the VITEK 2 GN card (bioMérieux) and Vitek 2 automated system (bioMérieux). Susceptibility towards antibiotics of particular strains was determined by the means of AST NO 93 card. In the case of resistance towards carbapenem, the MIC was marked by E-test with Mueller Hinton substrate. The occurrence of MBL was verified by the means of disc system with Mueller Hinton substrate. Results. We have shown that total number of Acinetobacter baumannii infections at hospital was 140 (10,31% of total results of cultures). Percentage of Acinetobacter baumannii infections at wards: Intensive Care Unit 48%, Surgical Departments 20%, Internal Diseases Department 16%, Neurology 13%, other wards -3%. The susceptibility percentage of Acinetobacter Baumannii against antibiotics: colistin 90%, imipenem 64%, meropenem 43%, ampicillin-sulbactam 28%, amikacin 27%, gentamicin 24%, cefepime 9%, ceftazidime 7%, ciprofloxacin 7% conclusions. Acinetobacter baumannii infections are a significant proportion of nosocomial infections. Most relate to surgical wards and ICUs. Acinetobacter baumannii is resistant against most antibiotics. The highest percentage of sensitivity demonstrated for colistin and carbapenems.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Acinetobacter Baumannii Nosocomial Infections

Sieniawski¹,

Kaczka²,

Rucińska³

et al. 2013

Polish Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…However, colistin-resistant A. baumannii strains are emerging as a result of increased use of this agent. In fact, 5.3% of A. baumannii isolates identified in U.S. hospitals in 2010 were reported to be resistant to colistin (5). Unfortunately, patients infected by colistin-resistant XDR strains of A. baumannii frequently succumb to the infection, as there are no effective treatment options.…”

mentioning

confidence: 99%

“…A. baumannii has an extraordinary ability to develop resistance to even the most potent antimicrobial agents, and as a result, multidrug resistance (MDR) and extensive drug resistance (XDR), the latter defined as nonsusceptibility to at least one agent in all but two or fewer antimicrobial categories (3), are commonplace. Of note, the rate of carbapenem resistance has dramatically increased in the last decade, exceeding 40% by 2009 in the United States (4)(5)(6). Infection due to XDR A. baumannii strains is typically treated with colistin, alone or in combination with other agents (1,7).…”

mentioning

confidence: 99%

Activities of Vancomycin-Containing Regimens against Colistin-Resistant Acinetobacter baumannii Clinical Strains

O’Hara

Ambe

Casella

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…The ability to treat infections due to members of the Acinetobacter baumannii-calcoaceticus complex has been complicated by extensive resistance to multiple classes of antibiotics (10)(11)(12)(13)(14)(15). Colistin and the carbapenems often remain the antibiotics of last choice, and the frequency of multidrugresistant strains with no therapeutic options has risen in recent years (11)(12)(13)(14)(15).…”

mentioning

confidence: 99%

Phase-Variable Control of Multiple Phenotypes in Acinetobacter baumannii Strain AB5075

2015

View full text Add to dashboard Cite

Acinetobacter baumannii strain AB5075 produces colonies with two opacity phenotypes, designated opaque and translucent. These phenotypes were unstable and opaque and translucent colony variants were observed to interconvert at high frequency, suggesting that a phase-variable mechanism was responsible. The frequency of phase variation both within colonies and in broth cultures increased in a cell density-dependent manner and was mediated by the accumulation of an extracellular factor. This factor was distinct from the known A. baumannii signaling molecule 3-OH C 12 -homoserine lactone. Opaque and translucent colony variants exhibited a number of phenotypic differences, including cell morphology, surface motility, biofilm formation, antibiotic resistance, and virulence in a Galleria mellonella model. Additional clinical isolates exhibited a similar phase-variable control of colony opacity, suggesting that this may be a common feature of A. baumannii. IMPORTANCEA novel phase-variable mechanism has been identified in Acinetobacter baumannii that results in an interconversion between opaque and translucent colony phenotypes. This phase variation also coordinately regulates motility, cell shape, biofilm formation, antibiotic resistance, and virulence. The frequency of phase variation is increased at high cell density via a diffusible extracellular signal. To our knowledge, this report presents the first example of phase variation in A. baumannii and also the first example of quorum sensing-mediated control of phase variation in a bacterium. The findings are important, as this phase-variable mechanism can be identified only via changes in colony opacity using oblique light; therefore, many researchers studying A. baumannii may unknowingly be working with different colony variants.

show abstract

Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010

Cited by 69 publications

References 15 publications

Acinetobacter Baumannii Nosocomial Infections

Acinetobacter Baumannii Nosocomial Infections

Activities of Vancomycin-Containing Regimens against Colistin-Resistant Acinetobacter baumannii Clinical Strains

Phase-Variable Control of Multiple Phenotypes in Acinetobacter baumannii Strain AB5075

Contact Info

Product

Resources

About